# US 2019/0378594 A1 · Methods of Identifying and Treating Patient Populations Amenable to Cancer Immunotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0378594 A1
- Document ID: US20190378594A1
- Status: Published application
- Kind: A1
- Application number: 16/479,211
- Filed: 2018-01-19
- Published: 2019-12-12
- Earliest claimed: 2017-01-19
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Matthew Spitzer; Lawrence Fong
- Web page: https://patentgrep.com/patent/US20190378594A1

## CPC

- G01N 33/5751: of the skin, e.g. melanoma
- G16B 25/10: Gene or protein expression profiling; Expression-ratio estimation or normalisation
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- C07K 16/2818: {against CD28 or CD152}
- G01N 33/505: {involving T-cells}
- G16B 5/10: Boolean models
- G16B 45/00: ICT specially adapted for bioinformatics-related data visualisation, e.g. displaying of maps or networks
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- G01N 2333/7155: for interleukins [IL]
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Methods for identifying cancer patients amenable to anti-cancer immunotherapy are provided along with methods of monitoring cancer therapy. Also provided are methods of treating cancer patients amenable to anti-cancer immunotherapy. The methods involve determining the level of CD127<low>PD-1<low>T cells. The patients are treated with an immune checkpoint inhibitor, such as an anti-CTLA-4 antibody, e.g. ipilimumab.

## Claims

### Claim 1

A method of identifying a human cancer subject amenable to an anti-cancer immunotherapy, comprising:
(a) obtaining a dataset comprising data representing the level of CD127low PD-1low T cells in the human cancer subject;
(b) obtaining a dataset comprising data representing the level of CD127low PD-1low T cells in a control, wherein the control is the human cancer patient at an earlier time, a distinct human cancer subject that is unresponsive to the anti-cancer immunotherapy, or a healthy human; and
(c) assessing the amenability of the human cancer subject to the anti-cancer immunotherapy based on the data, optionally, identifying the human cancer subject as amenable to anti-cancer immunotherapy when the level of CD127low PD-1low T cells is greater in the human cancer subject than the level of CCD127low PD-1low T cells in the control.

### Claim 2 (depends on 1)

The method of claim 1, wherein the method comprises:
(a) obtaining a dataset comprising data representing the level of CD127low PD-1low T cells in the human cancer subject;
(b) obtaining a dataset comprising data representing the level of CD4+CD127low PD-1low T cells in the control;
(c) identifying the subject as amenable to anti-cancer immunotherapy when the level of CD4+ CD127low PD-1low T cells is greater in the human cancer subject than the level of CD4+ CD127low PD-1low T cells in the control; and
(d) treating the human cancer subject with an anti-CTLA4 antibody.

### Claim 3 (depends on 1)

The method of claim 1, further comprising treating the human cancer subject with an anti-CTLA4 antibody, optionally ipilimumab.

### Claim 4 (depends on 1)

The method of claim 1 further comprising treating the human cancer subject with an anti-cancer immunotherapy, optionally an immune checkpoint inhibitor, and optionally the immune checkpoint inhibitor is an anti-CTLA-4 antibody, an anti-CTLA-4 antibody fragment that binds CTLA-4, an anti-PD-1 antibody, an anti-PD-1 antibody fragment that binds PD-1, an anti-PD-L1 antibody, or an anti-PD-L1 antibody fragment that binds PD-L1.

### Claim 5 (depends on 1)

The method of claim 1, further comprising identifying the human cancer subject as amenable to anti-cancer immunotherapy when the level of CD127low PD-1low T cells is greater in the human cancer subject than the level of CD127low PD-1low T cells in the control.

### Claim 6 (depends on 1)

The method of claim 1, wherein the T cells are CD4 positive cells.

### Claim 7 (depends on 6)

The method of claim 6 wherein the CD4 positive cells are regulatory T cells, optionally CD4+CD25+ regulatory T cells.

### Claim 8 (depends on 1)

The method of claim 1, wherein the control is the human cancer subject at an earlier time.

### Claim 9 (depends on 8)

The method of claim 8 wherein the time is prior to a cancer treatment.

### Claim 10 (depends on 1)

The method of claim 1, wherein the cancer is melanoma.

### Claim 11 (depends on 1)

The method of claim 1, wherein the human cancer subject has a tumor and the T cells are obtained intratumorally.

### Claim 12 (depends on 1)

The method of claim 1, wherein the T cells are obtained from a secondary lymphoid organ or from peripheral blood.

### Claim 13 (depends on 1)

The method of claim 1, wherein obtaining the dataset comprises receiving the dataset from a third party.

### Claim 14 (depends on 1)

The method of claim 1, wherein obtaining the dataset comprises processing a sample from the human cancer subject and/or control to experimentally determine the dataset.

### Claim 15 (depends on 14)

The method of claim 14, wherein the processing comprises use of flow cytometry.

### Claim 16

A method of monitoring anti-cancer immunotherapy in a human cancer subject comprising:
(a) obtaining a dataset comprising data representing the level of CD127low PD-1low T cells in the human cancer subject;
(b) obtaining a dataset comprising data representing the level of CD127low PD-1low flow T cells in a control, wherein the control is the human cancer subject at an earlier time, a distinct human cancer subject that is unresponsive to anti-cancer immunotherapy, or a healthy human, wherein a greater level of CD127low PD-1low T cells in the human cancer subject relative to control is indicative of a response to the anti-cancer immunotherapy; and/or a lower level of CD127low PD-1low T cells in the human cancer subject relative to control is indicative of a lack of response to the anti-cancer immunotherapy.

### Claim 17 (depends on 16)

The method of claim 16 wherein the T cells are CD4 positive cells.

### Claim 18 (depends on 17)

The method of claim 17 wherein the CD4 positive cells are regulatory T cells, optionally CD4+CD25+ regulatory T cells.

### Claim 19 (depends on 16)

The method of claim 16 wherein the control is the human cancer subject at an earlier time.

### Claim 20 (depends on 19)

The method of claim 19 wherein the time is prior to a cancer treatment.

### Claim 21 (depends on 16)

The method of claim 16 wherein the cancer is melanoma.

### Claim 22 (depends on 16)

The method of claim 16 wherein the human cancer subject has a tumor and the T cells are obtained intratumorally.

### Claim 23 (depends on 16)

The method of claim 16 wherein the T cells are obtained from a secondary lymphoid organ or from peripheral blood.

### Claim 24 (depends on 16)

The method of claim 16, wherein obtaining the dataset comprises receiving the dataset from a third party.

### Claim 25 (depends on 16)

The method of claim 16, wherein obtaining the dataset comprises processing a sample from the human cancer subject and/or control to experimentally determine the dataset.

### Claim 26 (depends on 25)

The method of claim 25, wherein the processing comprises use of flow cytometry.

### Claim 27

A method of treating cancer in a human cancer subject comprising: administering a therapeutically effective amount of a composition comprising an immune checkpoint inhibitor to the subject, wherein the human cancer subject has been determined to have a greater level of CD127low PD-1low cells than a control, wherein the control is the human cancer subject at an earlier time, a distinct human cancer subject that is unresponsive to anti-cancer immunotherapy, or a healthy human, thereby treating the cancer in the human cancer subject, optionally further comprising administering a soluble growth factor to the human cancer subject.

### Claim 28 (depends on 27)

The method of claim 27, further comprising determining that the human cancer subject has a greater level of CD127low PD-1low cells than the control prior to treatment with the immune checkpoint inhibitor, optionally wherein the inhibitor is an anti-CTLA4 antibody.

### Claim 29 (depends on 27)

The method of claim 27, further comprising administering a soluble growth factor to the human cancer subject.

### Claim 30 (depends on 27)

The method of claim 27 wherein the soluble growth factor is granulocyte-macrophage colony stimulating factor (GM-CSF).

### Claim 31 (depends on 27)

The method of claim 27 wherein the T cells are CD4 positive cells.

### Claim 32 (depends on 31)

The method of claim 31 wherein the CD4 positive cells are regulatory T cells, optionally CD4+CD25+ regulatory T cells.

### Claim 33 (depends on 27)

The method of claim 27 wherein the control is the human cancer subject at an earlier time.

### Claim 34 (depends on 33)

The method of claim 33 wherein the earlier time is prior to a cancer treatment.

### Claim 35 (depends on 27)

The method of claim 27 wherein the cancer is melanoma.

### Claim 36 (depends on 27)

The method of claim 27 wherein the human cancer subject has a tumor and the T cells are obtained intratumorally.

### Claim 37 (depends on 27)

The method of claim 27 wherein the T cells are obtained from a secondary lymphoid organ or from peripheral blood.

### Claim 38 (depends on 27)

The method of claim 27 wherein the treatment inhibits the growth of cancer cells.

### Claim 39 (depends on 27)

The method of claim 27 wherein the treatment inhibits the migration of cancer cells.

### Claim 40 (depends on 27)

The method of claim 27 wherein the immune checkpoint inhibitor is an anti-CTLA-4 antibody, an anti-CTLA-4 antibody fragment that binds CTLA-4, an anti-PD-1 antibody, an anti-PD-1 antibody fragment that binds PD-1, an anti-PD-L1 antibody, or an anti-PD-L1 antibody fragment that binds PD-L1.

### Claim 41 (depends on 27)

The method of claim 27 wherein the immune checkpoint inhibitor is ipilimumab.

### Claim 42 (depends on 28)

The method of claim 28, wherein the determining comprises receiving, from a third party, a dataset comprising data representing the level(s) of CD127low PD-1low cells.

### Claim 43 (depends on 28)

The method of claim 28, wherein the determining comprises processing a sample from the human cancer subject and/or control to experimentally determine a dataset comprising data representing the level(s) of CD127low PD-1low cells.

### Claim 44 (depends on 43)

The method of claim 43, wherein the processing comprises use of flow cytometry.

### Claim 45

A composition comprising: (a) a sample from a human cancer subject comprising T cells; (b) an anti-CD127 antibody; and (c) an anti-PD-1 antibody.

### Claim 46 (depends on 45)

The composition of claim 45, wherein the sample is from a tumor, a secondary lymphoid organ, or peripheral blood of the subject.

### Claim 47 (depends on 45)

The composition of claim 45, wherein T cells in the sample are CD4+.

### Claim 48 (depends on 45)

The composition of claim 45, wherein T cells in the sample are CD127low PD-1low, optionally as determined by flow cytometry.

### Claim 49 (depends on 45)

The composition of claim 45, wherein the cancer is melanoma.

### Claim 50 (depends on 45)

The composition of claim 45, wherein an anti-CD127 antibody and an anti-PD-1 antibody are each bound to a single T cell.

### Claim 51 (depends on 45)

The composition of claim 45, wherein each of the antibodies are distinctly labeled with one or more detectable labels.

### Claim 52 (depends on 45)

The composition of claim 45, further comprising a buffer.

### Claim 53 (depends on 45)

A flow cytometry device, comprising the composition of claim 45, wherein the device is configured to detect the antibodies.
